Quick Answer
Dyne Therapeutics, Inc. reported Diluted EPS of $3.47 per share (loss) for fiscal year 2025.
Dyne Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.47 | -3.0% |
| 2024 | -$3.37 | +14.7% |
| 2023 | -$3.95 | -22.3% |
| 2022 | -$3.23 | -10.2% |
| 2021 | -$2.93 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.76 | +20.8% | +21.6% |
| June 30, 2025 | -$0.97 | -38.6% | +7.6% |
| March 31, 2025 | -$1.05 | -29.6% | -9.4% |
| September 30, 2024 | -$0.96 | +3.0% | -37.1% |
| June 30, 2024 | -$0.70 | +35.2% | +13.6% |
| March 31, 2024 | -$0.81 | -3.8% | +18.2% |
| September 30, 2023 | -$0.99 | -23.7% | +8.3% |
| June 30, 2023 | -$1.08 | -6.9% | -38.5% |
- Dyne Therapeutics, Inc. showed a decrease of -3.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Dyne Therapeutics, Inc.’s diluted eps has declined by 18.4% (from $2.93 per share (loss) to $3.47 per share (loss)).
- The most recent figure is from Dyne Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: